Cytori Therapeutics, Inc. (CYTX) Addressing Scleroderma Hand Dysfunction through Late Stage Clinical Trial
Scleroderma is a chronic connective tissue disease that affects an estimated 300,000 people within the United States, according to the National Women’s Health Information Center. The disease is commonly associated with excessive collagen that narrows blood vessels, restricting the flow of blood to body tissues and organs and severely limiting the movement of patients’ fingers and hands. Cytori Therapeutics, Inc. (NASDAQ: CYTX) is addressing this critically underserved medical need through the continued development of ECCS-50. ECCS-50 utilizes Cytori’s proprietary Cell Therapy™ technology, which has been shown to improve blood flow, modulate the immune system and facilitate wound repair. As a…